This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration
logo_not_found
Event
Hybrid Event

Accelerate Ideas, Partnerships and Opportunities

Book your SLOT NOW
  • Start 9:00am - 6:00pm
  • Rome, Italy
    Registration Venue
     

    About Conference

    Sciinov Group is proud to announce the Oligonucleotide Therapeutics and Delivery Conference, 23-24 March, 2026 in Rome, Italy. This year OTDC 2026 annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 23 March, 2026 at Rome, Italy.


    Industry and academic experts deliver detailed case studies on antisense, RNA, GalNAc, aptamers, conju...

    Readmore

    Author's Login
    Abstract Tracking Tool

    Scientific Sessions

    ask & questions

    answer

    We are always looking for new industry leaders to join our speaker faculty to deliver presentations, lead panel discussions and moderate sessions or roundtables. 
    If you are interested in being considered as a speaker, submit your proposal/abstract Online

    answer

    We let speakers propose the topic they want to talk about. This process allows speakers to propose sessions that speak from their expertise and passion.
    Speaker can choose the topic of your choice in related to the conference subject or any of their recent research work to present at our conference.
    For details of scientific sessions covered please visit [not limited to, you can propose]  

     

    answer

    Please visit the page here

    answer

    Yes, as our conference is scheduled in Hybrid Mode, you can present and listen to full program virtually connecting via ZOOM live stream


    view all Faq's

    Recent Updates

    07 Apr
    2025

    Lexeo Therapeutics Reports Positive Interim Phase 1/2 Results for LX2006 in Friedreich’s Ataxia Cardiomyopathy, Paving the Way for Registrational Trial

    Lexeo Therapeutics reported positive interim Phase 1/2 data for LX2006 in Friedreich’s ataxia cardiomyopathy, showing improved cardiac function and increased frataxin levels, supporting advancement to a registrational studyReadmore

    08 Apr
    2025

    Avidity Biosciences has been granted Orphan Drug Designation in Japan for Delpacibart Etdesiran (del-desiran) for the treatment of Myotonic Dystrophy Type 1

    Avidity Biosciences' delpacibart etedesiran (del-desiran) has received Orphan Drug Designation in Japan for treating myotonic dystrophy type 1 (DM1), the first DM1 treatment to do so. It also holds similar designations from the FDA and EMA. Readmore

    09 Apr
    2025

    Amylyx Pharmaceuticals has announced the dosing of the first participant in the Phase 1, Multiple Ascending Dose LUMINA trial of AMX0114 in individuals with Amyotrophic Lateral Sclerosis (ALS)

    Amylyx Pharmaceuticals announced the dosing of the first participant in LUMINA, a Phase 1, multinational trial of AMX0114, an investigational antisense oligonucleotide targeting calpain-2 in ALS patients. Early cohort data is expected in 2025Readmore

    04 Apr
    2025

    A cellular regulator of mRNA vaccines has been discovered, opening up new therapeutic possibilities

    Dr. Kim V. Narry's team at the Institute for Basic Science has revealed a key cellular mechanism affecting mRNA vaccine function, offering insights to improve RNA-based treatments.Readmore


    view all Updates
    08:00

    Day 1: Innovations in Oligonucleotide Therapeutics

    08:00 - 09:00

    "Registration & Networking Breakfast Meet fellow attendees and start the day with informal networking."

    09:00 - 09:15

    "Keynote Session: The Future of Oligonucleotide Therapeutics Exploring advancements in RNA-based therapies, ASOs, and siRNA treatments."

    09:15 - 10:00

    "Keynote Session: The Future of Oligonucleotide Therapeutics Exploring advancements in RNA-based therapies, ASOs, and siRNA treatments."

    10:00 - 10:45

    "Session 1: Breakthroughs in RNAi and Antisense Oligonucleotides a. Advances in antisense oligonucleotides (ASOs) and siRNA b. Case studies on novel RNA-based therapeutics"

    10:45 - 11:15

    Coffee Break & Networking

    11:15 - 12:15

    "Panel Discussion: Overcoming Challenges in Oligonucleotide Drug Development a. Regulatory hurdles and approval pathways b. Manufacturing scalability and cost challenges c. Stability and delivery issues"

    12:15 - 13:15

    Lunch Break & Networking

    13:15 - 14:00

    "Industry Insights: Manufacturing & Scale-Up of Oligonucleotide Therapies a. GMP manufacturing and quality control challenges b. Trends in large-scale production"

    14:00 - 14:45

    "Session 3: AI & Computational Approaches in Oligonucleotide Drug Design a. Role of AI in target selection and design optimization b. Predictive modeling for therapeutic efficacy"

    14:45 - 15:15

    Afternoon Coffee Break

    15:15 - 16:00

    "Industry Case Study: Recent Successes in Oligonucleotide Therapies a. A biotech/pharma company shares insights on successful drug development."

    16:00 - 17:00

    "Roundtable Discussions & Interactive Q&A Breakout sessions focusing on specific therapeutic areas and delivery challenges."

    17:00 - 18:00

    "Networking Cocktail Reception A relaxed setting to connect with industry experts and researchers."

    08:30

    Day 2: Advances in Oligonucleotide Delivery & Clinical Applications

    08:30 - 09:00

    Morning Coffee & Networking

    09:00 - 09:45

    "Keynote Session: Next-Generation Delivery Systems for Oligonucleotides Exploring lipid nanoparticles, exosomes, and polymer-based carriers."

    09:45 - 10:30

    "Session 4: Overcoming Barriers in Extrahepatic Delivery a. Advances in tissue-specific delivery b. Strategies for targeting CNS, muscle, and lung tissues"

    10:30 - 11:00

    Networking Coffee Break

    11:00 - 12:00

    "Panel Discussion: Regulatory & Commercialization Strategies a. FDA/EMA regulatory pathways b. Pricing and market access challenges"

    12:00 - 13:00

    Lunch Break & Poster Sessions

    13:00 - 13:45

    "Session 5: Oligonucleotide Conjugation and Chemical Modifications a. Enhancing stability and specificity through novel chemical modifications b. Conjugation strategies for improved therapeutic outcomes"

    13:45 - 14:30

    "Industry Insights: Manufacturing & Scale-Up of Oligonucleotide Therapies a. GMP manufacturing and quality control challenges b. Trends in large-scale production"

    14:30 - 15:00

    Afternoon Coffee Break

    15:00 - 15:45

    "Emerging Technologies Showcase: Startups & Innovation Pitches a. New technologies in oligonucleotide discovery and delivery b. Emerging biotech startups present their innovations"

    15:45 - 16:30

    "Fireside Chat: The Future of Oligonucleotide-Based Precision Medicine a. Personalized medicine applications b. Future directions in gene-targeted therapies"

    16:30 - 17:00

    "Closing Remarks & Key Takeaways Summary of insights and discussions from the two-day event."

    17:00

    Thanks giving & Conference Closure

    Get more information

    make a booking now

    Market Reports

    view all Reports

    Subscribe to our News & Updates